Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus a randomized trial

Annals of Internal Medicine

Volumn 165, Issue 5, 2016, Pages 305-315

  Cusi, Kenneth ^a   Orsak, Beverly ^b   Bril, Fernando ^a   Lomonaco, Romina ^a   Hecht, Joan ^b   Ortiz Lopez, Carolina ^b   Tio, Fermin ^b   Hardies, Jean ^b   Darland, Celia ^b   Musi, Nicolas ^b   Webb, Amy ^b   Portillo Sanchez, Paola ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CYTOKERATIN 18; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PIOGLITAZONE; PLACEBO; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; AMINOTRANSFERASE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

ADIPOSE TISSUE; ADRENAL CORTEX CARCINOMA; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATYPICAL CHEST PAIN; BLADDER CANCER; CARDIOVASCULAR DISEASE; CHOLELITHIASIS; CHRONIC LOWER LIMB EDEMA; CLINICAL OUTCOME; CONCUSSION; CONTROLLED STUDY; DIABETIC PATIENT; DISSOCIATIVE AMNESIA; DIVERTICULITIS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENDOCRINE DISEASE; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; GASTRITIS; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GYNECOLOGIC DISEASE; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HEMATOLOGIC DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; INSULIN BLOOD LEVEL; INSULIN INFUSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIVER BIOPSY; LIVER FIBROSIS; LOW CALORY DIET; LOW DRUG DOSE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MIGRAINE; MUSCULOSKELETAL DISEASE; NEPHROLITHIASIS; NEUROLOGIC DISEASE; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; OPEN STUDY; ORAL GLUCOSE TOLERANCE TEST; OSTEOPOROSIS; OTOLARYNGOLOGIC DISEASE; OVARY CYST; PANCREATITIS; PARALLEL DESIGN; PATIENT COMPLIANCE; PERFORATION; PERIPHERAL EDEMA; PERIPHERIC NEUROPATHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; THORAX PAIN; THROMBOCYTOPENIA; UNIVERSITY HOSPITAL; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE RETENTION; UTERUS BLEEDING; VAGINA DISEASE; VAGINAL YEAST INFECTION; WEIGHT GAIN; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PREDIABETIC STATE;

BIOMARKERS; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDIABETIC STATE; THIAZOLIDINEDIONES; TRANSAMINASES; TRIGLYCERIDES; WEIGHT GAIN;

EID: 84985993965     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-1774     Document Type: Article

References (56)

1. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-90. [PMID: 24042449] doi:10.1038/nrgastro.2013.171.
2. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis. 2010;28:162-8. [PMID: 20460906] doi:10.1159/000282081.
3. Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004;40:578-84. [PMID: 15030972].
4. Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep. 2007;7:175-80. [PMID: 17547834].
5. Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564-70. [PMID: 18385424] doi:10.1681/ASN.2007101155.
6. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212-8. [PMID: 17277038].
7. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142:711-725. [PMID: 22326434] doi:10.1053/j.gastro.2012.02.003.
8. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2:262-5. [PMID: 15017611].
9. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology. 2008;48:792-8. [PMID: 18752331] doi:10.1002/hep.22429.
10. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corné r A, Bergholm R, et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care. 2008;31: 165-9. [PMID: 17934148].
11. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113-9. [PMID: 18384521] doi:10.1111/j.1478-3231.2008.01718.x.
12. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, et al; Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139-44. [PMID: 21478462] doi:10.2337/dc10-2229.
13. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology. 2003;37: 1286-92. [PMID: 12774006].
14. Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab. 2015;100:2231-8. [PMID: 25885947] doi:10.1210/jc.2015-1966.
15. Portillo P, Yavuz S, Bril F, Cusi K. Role of insulin resistance and diabetes in the pathogenesis and treatment of nonalcoholic fatty liver disease. Curr Hepatol Rep. 2014;13:159-70.
16. Ortiz-Lopez C, Lomonaco R, Orsak B, Finch J, Chang Z, Kochunov VG, et al. Prevalence of prediabetes and diabetes and metabolic profile of patients with nonalcoholic fatty liver disease (NAFLD). Diabetes Care. 2012;35:873-8. [PMID: 22374640] doi:10.2337/dc11-1849.
17. Gastaldelli A, Harrison S, Belfort-Aguiar R, Hardies J, Balas B, Schenker S, et al. Pioglitazone in the treatment of NASH: The role of adiponectin. Aliment Pharmacol Ther. 2010;32:769-75. [PMID: 20662773] doi:10.1111/j.1365-2036.2010.04405.x.
18. Lomonaco R, Bril F, Portillo-Sanchez P, Ortiz-Lopez C, Orsak B, Biernacki D, et al. Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes. Diabetes Care. 2016. [PMID: 26861926].
19. Bril F, Sninsky JJ, Baca AM, Superko HR, Portillo Sanchez P, Biernacki D, et al. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J Clin Endocrinol Metab. 2016;101:644-52. [PMID: 26672634] doi:10.1210/jc.2015-3111.
20. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology. 2008;134:424-31.[PMID:18242210]doi:10.1053/j.gastro.2007.11.038.
21. Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology. 2015;61:153-60. [PMID: 25145475] doi:10.1002/hep.27395.
22. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55: 2005-23. [PMID: 22488764] doi:10.1002/hep.25762.
23. Neuschwander-Tetri BA. NASH: The tribulations of conducting NASH trials. Nat Rev Gastroenterol Hepatol. 2014;11:274-6. [PMID: 24709815] doi:10.1038/nrgastro.2014.51.
24. Utzschneider KM, Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J Clin Endocrinol Metab. 2006;91: 4753-61. [PMID: 16968800].
25. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: The central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52:774-88. [PMID: 20683968] doi:10.1002/hep.23719.
26. Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59: 1174-97. [PMID: 24002776] doi:10.1002/hep.26717.
27. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59: 713-23. [PMID: 23929732] doi:10.1002/hep.26672.
28. Ratziu V, Caldwell S, Neuschwander-Tetri BA. Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related meth-odological issues. Hepatology. 2010;52:2206-15. [PMID: 21105109] doi:10.1002/hep.24042.
29. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:519-25. [PMID: 11232700].
30. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology. 2003;38:1008-17. [PMID: 14512888].
31. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology. 2004;39:188-96. [PMID: 14752837].
32. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135:1176-84.[PMID:18718471]doi:10.1053/j.gastro.2008.06.047.
33. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann- Heurtier A, Serfaty L, et al; LIDO Study Group. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology. 2008;135:100-10. [PMID: 18503774] doi:10.1053/j.gastro.2008.03.078.
34. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al; NASH CRN. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-85. [PMID: 20427778] doi:10.1056/NEJMoa0907929.
35. Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med. 2006;355:2297-307. [PMID: 17135584].
36. Dall TM, Yang W, Halder P, Pang B, Massoudi M, Wintfeld N, et al. The economic burden of elevated blood glucose levels in 2012: diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care. 2014;37:3172-9. [PMID: 25414388] doi:10.2337/dc14-1036.
37. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, et al; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364: 1104-15. [PMID: 21428766] doi:10.1056/NEJMoa1010949.
38. Yau H, Rivera K, Lomonaco R, Cusi K. The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus. Curr Diab Rep. 2013;13:329-41. [PMID: 23625197] doi:10.1007/s11892-013-0378-8.
39. Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20: 573-91. [PMID: 25242225] doi:10.1016/j.cmet.2014.08.005.
40. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-21. [PMID: 15915461].
41. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Hepatology. 2011;54:1610-9. [PMID: 21748765] doi:10.1002/hep.24544.
42. Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al; NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial. Lancet. 2015;385:956-65. [PMID: 25468160] doi:10.1016/S0140-6736(14)61933-4.
43. Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, et al; GOLDEN-505 Investigator Study Group. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-αand -δ induces resolution of nonalcoholic steatohepatitis without fibrosis worsening. Gastroenterology. 2016;150:1147-1159. [PMID: 2687 4076] doi:10.1053/j.gastro.2016.01.038.
44. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011;54:344-53. [PMID: 21520200] doi:10.1002/hep.24376.
45. Bril F, Ortiz-Lopez C, Lomonaco R, Orsak B, Freckleton M, Chintapalli K, et al. Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients. Liver Int. 2015;35:2139-46. [PMID: 25847730] doi:10.1111/liv.12840.
46. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011;34:916-22. [PMID: 21447663] doi:10.2337/dc10-1068.
47. Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:167-74. [PMID: 23973932] doi:10.1016/j.jhep.2013.07.042.
48. Leite NC, Villela-Nogueira CA, Pannain VL, Bottino AC, Rezende GF, Cardoso CR, et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 2011;31:700-6. [PMID: 21457442]doi:10.1111/j.1478-3231.2011.02482.x.
49. Stepanova M, Rafiq N, Makhlouf H, Agrawal R, Kaur I, Younoszai Z, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2013;58:3017-23. [PMID: 23775317] doi:10.1007/s10620-013-2743-5.
50. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J Hepatol. 2013;59:550-6. [PMID:23665288]doi:10.1016/j.jhep.2013.04.027.
51. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Ghany M, et al. The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis. Hepatology. 2007;46:424-9. [PMID: 17559148].
52. Fan JG, Li F, Cai XB, Peng YD, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol. 2007;22:1086-91. [PMID: 17608855].
53. Koliaki C, Roden M. Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Mol Cell Endocrinol. 2013;379:35-42. [PMID: 23770462] doi:10.1016/j.mce.2013.06.002.
54. Bril F, Portillo Sanchez P, Maximos M, Lomonaco R, Orsak B, Hecht J, et al. Metabolic predictors of response to pioglitazone treatment in patients with prediabetes or type 2 diabetes mellitus (T2DM) and nonalcoholic steatohepatitis (NASH). Diabetes. 2015;64:A337.
55. Levin D, Bell S, Sund R, Hartikainen SA, Tuomilehto J, Pukkala E, et al; Scottish Diabetes Research Network Epidemiology Group. Pioglitazone and bladder cancer risk: A multipopulation pooled, cumulative exposure analysis. Diabetologia. 2015;58:493-504. [PMID: 25481707] doi:10.1007/s00125-014-3456-9.
56. Lewis JD, Habel LA, Quesenberry CP, Strom BL, Peng T, Hedderson MM, et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA. 2015;314: 265-77. [PMID: 26197187] doi:10.1001/jama.2015.7996.